Table 4 Pairwise hazard ratio for disease-specific survival stratified by Clinical Prognostic Stage and Prognostic Score Category in the two cohorts.
SEER | UAB | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Clinical Prognostic Stage | Prognostic Score Category | Clinical Prognostic Stage | Prognostic Score Category | ||||||||
Stage | HR (95% CI) | P | Category | HR (95% CI) | P | Stage | HR (95% CI) | P | Category | HR (95% CI) | P |
IB vs. IA | 2.12 (1.82, 2.48) | <2 × 10−16 | II vs. I | 2.78 (2.44, 3.18) | <2 × 10−16 | IB vs. IA | 4.44 (2.50, 7.89) | 3.62 × 10−7 | II vs. I | 3.66 (2.23, 5.99) | 2.61 × 10−7 |
IIA vs. IB | 1.49 (1.28, 1.72) | 1.41 × 10−7 | III vs. II | 2 (1.80, 2.22) | <2 × 10−16 | IIA vs. IB | 1.43 (0.92, 2.22) | 0.112 | III vs. II | 2.5 (1.75, 3.57) | 5.19 × 10−7 |
IIB vs. IIA | 1.89 (1.65, 2.17) | <2 × 10−16 | IV vs. III | 2.34 (2.14, 2.57) | <2 × 10−16 | IIB vs. IIA | 2.37 (1.57, 3.57) | 3.65 × 10−5 | IV vs. III | 2.04 (1.49, 2.80) | 9.82 × 10−6 |
IIIA vs. IIB | 1.35 (1.15, 1.58) | 0.000173 | V vs. IV | 2 (1.83, 2.19) | <2 × 10−16 | IIIA vs. IIB | 1.63 (1.05, 2.53) | 0.0305 | V vs. IV | 2.84 (2.01, 4.00) | 2.63 × 10−9 |
IIIB vs. IIIA | 1.63 (1.42, 1.87) | 3.67 × 10−16 | VI vs. V | 1.94 (1.77, 2.13) | <2 × 10−16 | IIIB vs. IIIA | 1.27 (0.83, 1.96) | 0.281 | VI vs. V | 2.92 (1.79, 4.75) | 1.72 × 10−5 |
IIIC vs. IIIB | 2.39 (2.15, 2.66) | <2 × 10−16 | VII vs. VI | 1.37 (1.21, 1.55) | 4.3 × 10−7 | IIIC vs. IIIB | 2.67 (1.77, 4.04) | 3.00 × 10−6 | VII vs. VI | 3.29 (1.59, 6.84) | 0.00137 |
IV vs. IIIC | 1.49 (1.35, 1.64) | 4.36 × 10−16 | VIII vs. VII | 1.93 (1.64, 2.27) | 2.61 × 10−15 | IV vs. IIIC | 1.58 (1.03, 2.40) | 0.0344 | VIII vs. VII | NA | NA |
